Cargando…

Impact of implantable cardioverter defibrillator on survival in patients with non‐ischemic dilated cardiomyopathy

Detalles Bibliográficos
Autores principales:	Kataoka, Naoya, Imamura, Teruhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577542/ https://www.ncbi.nlm.nih.gov/pubmed/37306258 http://dx.doi.org/10.1002/clc.24032

Ejemplares similares

Response: Impact of implantable cardioverter defibrillator on survival in patients with nonischemic dilated cardiomyopathy
por: Salehi Omran, Hossein, et al.
Publicado: (2023)

Implantable cardioverter-defibrillators in non-ischaemic cardiomyopathy: a need or not?
por: de Groot, Joris R.
Publicado: (2023)

Predictors of Implantable Cardioverter-Defibrillator Use in Patients with Ischemic Cardiomyopathy
por: Kelly, Ryan, et al.
Publicado: (2010)

Induced atrial fibrillation during defibrillation test on implantation of subcutaneous implantable cardioverter defibrillator
por: Kim, Ki-Hun, et al.
Publicado: (2020)

Survival Following Implantable Cardioverter‐Defibrillator Implantation in Patients With Amyloid Cardiomyopathy
por: Higgins, Angela Y., et al.
Publicado: (2020)

Implantable cardioverter–defibrillator in hypertrophic cardiomyopathy
por: Sanchez, Diego Jimenez, et al.
Publicado: (2018)

Selvester score predicts implantable cardioverter defibrillator shocks in patients with non‐ischemic cardiomyopathy
por: Arısoy, Fazıl, et al.
Publicado: (2021)

Clinical utility of remote monitoring using multiparametric implantable defibrillators algorithm
por: Imamura, Teruhiko
Publicado: (2022)

Prognosis Determinants after Cardioverter-Defibrillators Implantation in Brazil
por: Migowski, Arn, et al.
Publicado: (2017)

Bridge to avoid ICD implantation with wearable cardioverter defibrillators
por: Zoppo, Franco, et al.
Publicado: (2020)

Cardiac Sarcoidosis: Indications for Implantable Cardioverter-Defibrillator Therapy
por: Yalta, Kenan, et al.
Publicado: (2022)

The impact of implantable cardioverter defibrillator on the prognosis of nonischemic dilated cardiomyopathy patients compared with standard medical treatments
por: Salehi Omran, Hossein, et al.
Publicado: (2023)

Implantable cardioverter defibrillator implantation and degree of left ventricular scarring predict survival in patients with severe ischemic cardiomyopathy
por: Kwon, Deboarh H, et al.
Publicado: (2011)

Incidence of appropriate cardioverter-defibrillator shocks and mortality in patients with implantable cardioverter-defibrillators with ischemic cardiomyopathy versus nonischemic cardiomyopathy at 33-month follow-up
por: Gandhi, Kaushang, et al.
Publicado: (2010)

Factors associated with implantable cardioverter-defibrillator shocks in patients suffering from non-ischemic cardiomyopathy
por: Rezaee, Mahmood, et al.
Publicado: (2022)

Higher defibrillation threshold in methamphetamine cardiomyopathy patients with implantable cardioverter-defibrillator
por: Malhotra, Rakesh, et al.
Publicado: (2017)

Follow-up of implantable cardioverter-defibrillator therapy: comparison of coronary artery disease and dilated cardiomyopathy
por: Verhagen, M. P., et al.
Publicado: (2014)

Obsessive-Compulsive Disorder as a Risk Factor in Patients with Implantable Cardioverter Defibrillator
por: Banihashemian, K, et al.
Publicado: (2011)

Fracture of DF-4 implantable cardioverter defibrillator lead in a pediatric patient
por: Dagriri, Khalid, et al.
Publicado: (2015)

Trends in implantable cardioverter defibrillator and cardiac resynchronisation therapy lead parameters for patients with arrhythmogenic and dilated cardiomyopathies
por: Lane, Jem D., et al.
Publicado: (2018)

Impact of Shocks on Mortality in Patients with Ischemic or Dilated Cardiomyopathy and Defibrillators Implanted for Primary Prevention
por: Streitner, Florian, et al.
Publicado: (2013)

Role of Implantable Cardioverter Defibrillators in the Treatment of Hypertrophic Cardiomyopathy
por: Ghosh, Joydeep, et al.
Publicado: (2005)

An implantable cardioverter-defibrillator for primary prevention in non-ischemic cardiomyopathy: A systematic review and meta-analysis
por: Wasiak, Michał, et al.
Publicado: (2023)

Subcutaneous implantable cardioverter-defibrillator (S-ICD) for secondary prevention of sudden cardiac death
por: Kempa, Maciej, et al.
Publicado: (2016)

To the Editor— Strategy for revision of subcutaneous implantable cardioverter-defibrillator following inappropriate shock
por: Winter, Joachim, et al.
Publicado: (2019)

Reply to Yalta and Yetkin—Cardiac Sarcoidosis: Indications for Implantable Cardioverter-Defibrillator Therapy
por: Duffett, Stephen A., et al.
Publicado: (2022)

Think twice before implanting leads in a swimmer: challenges in lead implantation of an implantable cardioverter-defibrillator
por: Varvarousis, Dimitrios, et al.
Publicado: (2021)

Primary prevention implantable cardioverter-defibrillator use in non-ischemic dilated cardiomyopathy based on arrhythmic risk stratification and left ventricular reverse remodeling prediction
por: Muhammed, Ahmed, et al.
Publicado: (2022)

Evolving use and indications for implantable cardioverter defibrillators
por: de Groot, J. R.
Publicado: (2018)

Myocardial Scar Characterization and Future Ventricular Arrhythmia in Patients With Ischemic Cardiomyopathy and an Implantable Cardioverter-Defibrillator
por: Noordman, Alwin B. P., et al.
Publicado: (2021)

How to Improve Clinical Outcomes in Patients with Tachycardia-Induced Cardiomyopathy. Comment on Katz et al. Long-Term Outcomes of Tachycardia-Induced Cardiomyopathy Compared with Idiopathic Dilated Cardiomyopathy. J. Clin. Med. 2023, 12, 1412
por: Kataoka, Naoya, et al.
Publicado: (2023)

Impact of Aerobic Interval Training on the Endothelial Function in Patients with Atrial Fibrillation
por: Doi, Yuki, et al.
Publicado: (2023)

Watchful Waiting in an Unusual Cause of Hypoxemia after Implantable Cardioverter-Defibrillator Lead Extraction
por: Bejko, Jonida, et al.
Publicado: (2019)

Letter to the Editor: Inappropriate subcutaneous implantable cardioverter‐defibrillator discharge related to myopotential oversensing
por: Chery, Godefroy, et al.
Publicado: (2020)

Reply to the Editor— Strategy for revision of subcutaneous implantable cardioverter-defibrillator following inappropriate shock
por: Do, Khuyen, et al.
Publicado: (2019)

CMR-Based Risk Stratification of Sudden Cardiac Death and Use of Implantable Cardioverter–Defibrillator in Non-Ischemic Cardiomyopathy
por: Keil, Laura, et al.
Publicado: (2021)

Implantable cardioverter-defibrillators /
Publicado: (1994)

Implantable cardioverter defibrillator for primary prevention in patients with non-ischemic cardiomyopathy in the era of novel therapeutic agents- meta-analysis
por: Kolben, Yotam, et al.
Publicado: (2023)

Clinical and Hospital Factors Affecting Treatment with Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy Patients
por: Lee, Jae-Hyuk, et al.
Publicado: (2020)

Neutrophil to lymphocyte ratio predicts appropriate therapy in idiopathic dilated cardiomyopathy patients with primary prevention implantable cardioverter defibrillator
por: Uçar, Fatih M., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_eo2fimhl5ulv771ph3lbj5r88u